Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;9(1):e002032.
doi: 10.1136/bmjdrc-2020-002032.

Glycemic variability and cardiovascular disease in patients with type 2 diabetes

Marcela Martinez  1 , Jimena Santamarina  1 , Adrian Pavesi  2 , Carla Musso  2 , Guillermo E Umpierrez  3
Affiliations
Review

Glycemic variability and cardiovascular disease in patients with type 2 diabetes

Marcela Martinez et al. BMJ Open Diabetes Res Care. 2021 Mar.

Abstract

Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.

Keywords: cardiovascular system; diabetes mellitus; diagnostic techniques and procedures; type 2.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. International Diabetes Federation . IDF diabetes atlas teB, Belgium, 2019. Available: https://www.diabetesatlas.org
    1. Chudleigh RA, Bain S. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. Expert Opin Drug Saf 2017;16:627–35. 10.1080/14740338.2017.1313225 - DOI - PubMed
    1. Chan JCN, Lim L-L, Wareham NJ, et al. . The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 2021;396:2019–82. 10.1016/S0140-6736(20)32374-6 - DOI - PubMed
    1. Huang D, Refaat M, Mohammedi K, et al. . Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int 2017;2017:1–9. 10.1155/2017/7839101 - DOI - PMC - PubMed
    1. Morrish NJ, Wang SL, Stevens LK, et al. . Mortality and causes of death in the who multinational study of vascular disease in diabetes. Diabetologia 2001;44 Suppl 2:S14–21. 10.1007/PL00002934 - DOI - PubMed

Publication types

MeSH terms